O-Methylnordehydrobufotenine

Last updated

O-Methylnordehydrobufotenine
O-Methylnordehydrobufotenine.svg
Clinical data
Other namesO-Methyldehydrobufotenidine; 6-Methoxy-5-methyl-1,2,3,4,5-tetrahydropyrrolo[4,3,2-d,e]-quinoline
ATC code
  • None
Identifiers
  • 9-methoxy-7-methyl-2,7-diazatricyclo[6.3.1.04,12]dodeca-1(12),3,8,10-tetraene
PubChem CID
ChemSpider
Chemical and physical data
Formula C12H14N2O
Molar mass 202.257 g·mol−1
3D model (JSmol)
  • CN1CCC2=CNC3=C2C1=C(C=C3)OC
  • InChI=1S/C12H14N2O/c1-14-6-5-8-7-13-9-3-4-10(15-2)12(14)11(8)9/h3-4,7,13H,5-6H2,1-2H3
  • Key:PRPCWBYVLURNKE-UHFFFAOYSA-N

O-Methylnordehydrobufotenine, also known as O-methyldehydrobufotenidine or as 6-methoxy-5-methyl-1,2,3,4,5-tetrahydropyrrolo[4,3,2-d,e]-quinoline, is a tricyclic cyclized tryptamine and analogue of 5-MeO-DMT and bufotenine. [1] [2] [3] [4] It produces hallucinogen-like effects in monkeys and rodents. [1] [3] [4] However, although more potent than mescaline, O-methylnordehydrobufotenine was far less active than its open-chain analogue 5-MeO-DMT. [4] The drug is not known to have been tested in humans. [3] O-Methylnordehydrobufotenine was first described in the scientific literature by 1969. [1] [3] [4]

Contents

See also

References

  1. 1 2 3 Nichols DE (May 1973). Potential Psychotomimetics: Bromomethoxyamphetamines and Structural Congeners of Lysergic Acid (Thesis). University of Iowa. p. 10. OCLC   1194694085. In addition, Lee, et al,(31) have prepared O-methyl nordehydrobufotenin 6 and found it to be active. Although it does not satisfy correlate 1 of Chothia and Pauling, it has the required aromatic system and point of electron density at the 4 indole position.
  2. ↑ Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN   0-9630096-9-9. OCLC   38503252. "O-Methylnordehydrobufotenine: This is a rearrangement product of Dehydrobufotenine, which may be a natural product or it may be an artifact of analysis."
  3. 1 2 3 4 Trout K (2007). "O-Methyl-nordehydrobufotenine: 6-Methoxy-5-methyl-1,2,3,4,5-tetrahydropyrrolo[4,3,2-d,e]-quinoline.". Some Simple Tryptamines: A Brief Overview & Resource Compendium FS-X7. Activity: Hallucinogenic in animals. # 409 in Usdin & Efron 1979; citing Lee et al. 1969. Despite not actually ever being proven to be a hallucinogen in either animals or humans, this is interesting as, while it remains unreported as a naturally occurring alkaloid, this molecule is a simple rearrangement product of dehydrobufotenine. It suggests that it too may be physiologically active albeit possibly moderately toxic.
  4. 1 2 3 4 Lee FG, Daly JW, Manian AA (March 1969). "The synthesis of O-methylnordehydrobufotenine, a new psychoactive indole". Journal of Medicinal Chemistry. 12 (2): 321–322. doi:10.1021/jm00302a030. PMID   4977410. Because of the high CNS activity shown by N,N-dimethyl-5-methoxytryptamine, the synthesis of the structurally related tricyclic indole, O-methylnordehydrobufotenine (6-methoxy-5-methyl-1,3,4,5-tetrahydropyrrolo[4,3,2-d,e]quinoline, IIc), was undertaken. [...] Pharmacologic activity was determined in squirrel monkeys trained in the Wisconsin General Test Apparatus [...] The median effective dose (ED50) of IIc that disrupted the ability to discriminate between disks of different sizes was 33.8 μmoles/kg.12 In this test, the O-methylnordehydrobufotenine (IIc) is approximately twice as active as mescaline (ED50 71.0 μmoles/kg),11 but is much less active than its open-chain analog, N,N-dimethyl-5-methoxytryptamine, which from published data5,8 can be estimated to be much more than 30 times as active a hallucinogen as mescaline. When injected subcutaneously into NIH general purpose white mice, IIc at 20 mg/kg causes only slight overt changes (reduction in spontaneous activity) while N,N-dimethyl-5-methoxytryptamine at 10 mg/kg causes profound effects. At this dosage the mice lose the ability to move normally and engage in locomotor activity with legs extended laterally.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.